Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Most common side effects (12mg dose, across TRIUMPH-4 and TRIUMPH-1): Nausea: 43% TRIUMPH-4 / ~38% TRIUMPH-1 (mostly during dose escalation) Diarrhea: 33% / ~28% (peaks weeks 48, improves by week 16) Dysesthesia: 20.9% (tingling sensations onset variable, long-term persistence unknown) Vomiting: 21% / ~25% (decreases after month 3) Constipation: 25% Discontinuation rates: 18.2% in TRIUMPH-4 (osteoarthritis population), 11.3% in TRIUMPH-1 (general obesity population)
Tendon and Ligament Regeneration Pathways In rodent models of tendon injury, BPC-157 demonstrated increased fibroblast activity and collagen organization
Ascletis reported enhanced fat loss with ASC47 in semaglutide combo studies
Liraglutide and semaglutide are GLP-1 RAs whereas tirzepatide is a combined agonist to both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors
